Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1998-05-05
Mullis, Jeffrey C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 530330, 530331, 530332, A61K 3806, A61K 3807
Patent
active
057474583
ABSTRACT:
Compounds of the invention inhibit urokinase plasminogen activator: ##STR1## where R.sub.1 is lower alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, aryl-alkenyl, aryl-alkynyl, aryl-cycloalkyl, unsubstituted or substituted with 1-3 halo, OH, NH.sub.2, lower alkyl, halo-lower alkyl, lower alkoxy, lower alkylamino, lower alkylthio, CN or NO.sub.2 ;
REFERENCES:
patent: 4708871 (1987-11-01), Geysen
patent: 4833092 (1989-05-01), Geysen
patent: 5194392 (1993-03-01), Geysen
Appella et al., "The Receptor-binding Sequence of Urokinase", J Biol Chem (Apr. 5, 1987) 262:4437-40.
Behrendt et al., "Binding of the Urokinase-type Plasminogen Activator to Its Cell Surface Receptor is Inhibited by Low Doses of Suramin", J Biol Chem (Mar. 15, 1993) 268:5985-89.
Carmeliet et al., "Biological Effects of Inactivation of the Genes for Tissue-type Plasminogen Activator, Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Mice", Fibrinolysis (June, 1993) 7 Suppl. 1:27-28.
Cekuoliene et al., "Oxamido and Succinamidotetraacetic Acids and Their Derivatives", Chemical Abstracts (Jun. 1974) 80:382, Abstract No. 145348F.
Crowley et al., "Prevention of Metastasis by Inhibition of the Urokinase Receptor", Proc Natl Acad Sci USA (Jun. 1993) 90:5021-25.
Foekens et al., "Prognostic Value of Urokinase-type Plasminogen Activator in 671 Primary Breast Cancer Patients", Cancer Res (Nov. 1, 1992) 52:6101-05.
Goodson et al., "High-affinity Urokinase Receptor Antagonists Identified With Bacteriophage Peptide Display", Proc Natl Acad Sci USA (Jul., 1994) 91:7129.
Kobayashi et al., "Saturation of Tumour Cell Surface Receptors for Urokinase-type Plasminogen Activator by Amino-terminal Fragment and Subsequent Effect on Reconstituted Basement Membranes Invasion", Br J Cancer (Mar., 1993) 67:537-44.
Mignatti et al., "Expression of the Urokinase Receptor in Vascular Endothelial Cells is Stimulated by Basic Fibroblast Growth Factor", J Cell Biol (Jun., 1991) 113:1193-202.
Min et al., "cDNA for Mo3, A Monocyte Activation Anitgen, Encodes the Human Receptor for Urokinase Plasminogen Activator", J Immunol (Jun. 1, 1992) 148:3636-42.
Niedbala et al., "Tumor Necrosis Factor Induction of Endothelial Cell Urokinase-type Plasminogen Activator Mediated Proteolysis of Extracellular Matrix and Its Antagonism by .gamma.-Interferon", Blood (Feb. 1, 1992) 79:678-87.
Nykj.ae butted.r et al., "An Activation Antigen in Human T Lymphocytes .sup.1 ", J Immunol (Jan. 15, 1994) 152:505-16.
Odekon et al., "Urokinase-type Plasminogen Activator Mediates Basic Fibroblast Growth Factor-Induced Bovine Endothelial Cell Migration Independent of Its Proteolytic Activity", J Cell Physiol (Feb., 1992) 150:258-63.
Ossowski et al., Antibodies to Plasminogen Activator Inhibit Human Tumor Metastasis:, Cell (Dec., 1983) 35:611-19.
Ossowski, "In Vivo Invasion of Modified Chorioallantoic Membrane by Tumor Cells: the Role of Cell Surface-bound Urokinase", J Cell Biol (Dec., 1988) 107:2437-45.
Ploug et al., "Ligand Interaction between Urokinase-Type Plasminogen Activator and Its Receptor Probed with 8-Anilino-1-naphthalenesulfonate. Evidence for a Hydrophobic Binding Site Exposed Only on the Intact Receptor", Biochemistry (Aug., 1994) 33:8991-97.
Pyke et al., "Urokinase-type Plasminogen Activator is Expressed in Stromal Cells and Its Receptor in Cancer Cells at Invasive Foci in Human Colon Adenocarcinomas", Am J Path (May, 1991) 138:1059-67.
Pyke et al., "Receptor for Urokinase is Present in Tumor-associated Macrophages in Ductal Breast Carcinoma.sup.1 ", Cancer Res (Apr. 15, 1993) 53:1911-15.
Rabbani et al., "Structural Requirements for the Growth Factor Activity of the Amino-terminal Domain of Urokinase", J Biol Chem (Jul. 15, 1992) 267:14151-56.
Schlechte et al., "Invasion of Extracellular Matrix by Colon Cancer Cells: Dependence on Urokinase Receptor Display", Cancer Comm (May, 1990) 2:173-79.
Takano et al., "Suramin, an Anticancer and Angiosuppressive Agent, Inhibits Endothelial Cell Binding of Basic Fibroblast Growth Factor, Migration, Proliferation, and Induction of Urokinase-type Plasminogen Activator.sup.1 ", Cancer Res (May 15, 1994) 54:2654-60.
Weinstat-Saslo et al., "Angiogenesis and Colonization in the Tumor Metastatic Process: Basic and Applied Advances", FASEB J (Apr., 1994) 8:401-407.
Martin Eric J.
Rosenberg Steve
Spear Kerry L.
Blackburn Robert P.
Chiron Corporation
Chung Ling-Fong
Mullis Jeffrey C.
LandOfFree
Urokinase receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urokinase receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urokinase receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-54586